Jakafi 20 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FFBP7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $24,677
Award facts
- Contract value 100% obligated
- $24,676.82 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $24,676.82 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Jakafi (ruxolitinib) 20 mg tablets in a quantity of 60 units. This firm fixed-price delivery order, issued on December 4, 2025, with an ultimate completion date of December 5, 2025, was awarded without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The performance location is Park Ridge, Illinois, where DMS Pharmaceutical Group maintains its operations as a registered System for Award Management vendor since July 2001.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide recurring pharmaceutical supply to Department of Defense military healthcare facilities worldwide. The parent IDC, designated SPE2DR and awarded on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, comprising a 30-month base period with three optional 30-month renewal periods. DMS Pharmaceutical Group's established performance across numerous delivery orders for branded and generic prescription medications, specialty pharmaceuticals, biologics, and medical consumables positions the company as a critical supplier within the federal military medical supply chain.
Quick answers
Who was awarded contract SPE2DR26FFBP7?
SPE2DR26FFBP7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 4, 2025.
How much is contract SPE2DR26FFBP7 worth?
The government has obligated $24,677 on SPE2DR26FFBP7.
Is contract SPE2DR26FFBP7 an order under another contract?
Yes. SPE2DR26FFBP7 is a delivery order under SPE2DR25D9239, an indefinite delivery contract.
Was contract SPE2DR26FFBP7 competed?
The extent of competition for SPE2DR26FFBP7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award